AXIOS October 2, 2022
Alison Snyder

Competition is intensifying in the DNA sequencing industry, which has long been dominated by sequencing behemoth Illumina.

Driving the news: Illumina, which has an estimated 80% share of the global gene sequencing market, unveiled a new line of instruments today that it says will cut the cost of genome sequencing — the latest in a flurry of announcements from an industry in pursuit of faster and cheaper offerings.

What they’re saying: “It’s Illumina’s response to the competition,” says Jay Shendure, a professor of genome sciences at the University of Washington.

  • Element Biosciences, a startup with a benchtop sequencer already on the market, announced updated specifications this week that CEO Molly He says will support its market play to offer...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Patient / Consumer, Pharma / Biotech, Precision Medicine, Provider
Estonian Biobank to Sequence 10,000 Genomes as Part of Precision Medicine Project
Precision Immune Start-Up Mirador Launches with $400M+
The future of companion diagnostic (CDx) development: Why commercialization is key
STAT+: Drug development was once a marathon. New tools and timelines are turning it into a sprint
Precision Medicine Startup Mirador Unveils $400M for R&D of New I&I Drugs

Share This Article